New NUBEQA® (darolutamide) Subgroup Analyses from the P

New post hoc subgroup analyses from Phase III ARASENS trial in mHSPC show that NUBEQA plus androgen deprivation therapy (ADT) and docetaxel compared to ADT and docetaxel increased overall survival (OS) in specific subgroups with various types of metastatic disease burden and risk1Incidence of adverse events was simi...

Related Keywords

Australia , Finland , United States , New Zealand , Finnish , Australian , American , Bayer Cross , Bayer Healthcare Pharmaceuticals , Orion Corporation , American Cancer Society , Prostate Cancer Trials Group , American Society , Clinical Oncology Genitourinary , Cancers Symposium , New Zealand Urogenital , Heart Disease , Fetal Toxicity , Combinedp Gp , Prescribing Information , Plus Androgen Deprivation Therapy , Metastatic Hormone Sensitive Prostate Cancer , Disease Volume , Risk Subgroups , Hormone Sensitive Prostate , Metastatic Castration Sensitive Prostate Cancer , Cancer Statistics , Mortality Worldwide , Cancer Journal , Prostate Cancer , Accessed January , Cancer Society , Hormone Therapy , Cancer Incidence , Mortal Wkly , Castration Sensitive Prostate Cancer , Optimizing Patient Selection ,